Literature DB >> 17408372

Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Shaw-Wei D Tsen1, Augustine H Paik, Chien-Fu Hung, T-C Wu.   

Abstract

DNA vaccines represent a potentially promising approach for antigen-specific immunotherapy. Advances in our knowledge of the adaptive immune system have indicated that professional antigen-presenting cells, especially dendritic cells (DCs), play a key role in the generation of antigen-specific immune responses. Thus, the modification of the properties of DCs represents an important strategy for enhancing the potency of DNA vaccines. This review discusses strategies to increase the number of antigen-expressing DCs, enhance antigen expression, processing and presentation in DCs, promote the activation and function of DCs, and improve DC and T-cell interaction, in order to optimize DNA vaccine-elicited immune responses. Continuing progress in our understanding of DC and T-cell biology serves as a foundation for further improvement of DNA vaccine potency, which may lead to future clinical applications of DNA vaccines for the control of infectious diseases and malignancies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17408372      PMCID: PMC3190226          DOI: 10.1586/14760584.6.2.227

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  125 in total

Review 1.  The dendritic cell system and its role in immunogenicity.

Authors:  R M Steinman
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

2.  DNA-based immunization by in vivo transfection of dendritic cells.

Authors:  C Condon; S C Watkins; C M Celluzzi; K Thompson; L D Falo
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

3.  Intercellular trafficking and protein delivery by a herpesvirus structural protein.

Authors:  G Elliott; P O'Hare
Journal:  Cell       Date:  1997-01-24       Impact factor: 41.582

4.  Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes.

Authors:  I F Ciernik; J A Berzofsky; D P Carbone
Journal:  J Immunol       Date:  1996-04-01       Impact factor: 5.422

5.  Contribution of CpG motifs to the immunogenicity of DNA vaccines.

Authors:  D M Klinman; G Yamshchikov; Y Ishigatsubo
Journal:  J Immunol       Date:  1997-04-15       Impact factor: 5.422

6.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells.

Authors:  P Panina-Bordignon; A Tan; A Termijtelen; S Demotz; G Corradin; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1989-12       Impact factor: 5.532

Review 7.  Assembly, transport, and function of MHC class II molecules.

Authors:  P Cresswell
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

8.  Identification and characterization of a cDNA clone derived from the Marek's disease tumour cell line RPL1 encoding a homologue of alpha-transinducing factor (VP16) of HSV-1.

Authors:  D Koptidesová; J Kopácek; V Zelník; N L Ross; S Pastoreková; J Pastorek
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.

Authors:  T C Wu; F G Guarnieri; K F Staveley-O'Carroll; R P Viscidi; H I Levitsky; L Hedrick; K R Cho; J T August; D M Pardoll
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

10.  Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization.

Authors:  T W Tobery; R F Siliciano
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307

View more
  37 in total

1.  Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity.

Authors:  Shenghe Tian; Zuqiang Liu; Cara Donahue; Louis D Falo; Zhaoyang You
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

2.  Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.

Authors:  Daejin Kim; Talia Hoory; Archana Monie; Jenny Pan-Yun Ting; Chien-Fu Hung; T-C Wu
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

3.  Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.

Authors:  Yong Sung Park; Jin Hyup Lee; Chien-Fu Hung; T-C Wu; Tae Woo Kim
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441

4.  Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells.

Authors:  Chi-Mu Chuang; Talia Hoory; Archana Monie; Annie Wu; Mei-Cheng Wang; Chien-Fu Hung
Journal:  Vaccine       Date:  2008-12-03       Impact factor: 3.641

5.  Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination.

Authors:  Chi-Mu Chuang; Archana Monie; Chien-Fu Hung; T-C Wu
Journal:  J Biomed Sci       Date:  2010-04-28       Impact factor: 8.410

Review 6.  Therapeutic human papillomavirus vaccines: current clinical trials and future directions.

Authors:  Chien-Fu Hung; Barbara Ma; Archana Monie; Shaw-Wei Tsen; T-C Wu
Journal:  Expert Opin Biol Ther       Date:  2008-04       Impact factor: 4.388

7.  Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses.

Authors:  D Kim; A Monie; L He; Y-C Tsai; C-F Hung; T-C Wu
Journal:  Gene Ther       Date:  2008-02-14       Impact factor: 5.250

8.  Posttranscriptional regulatory elements enhance antigen expression and DNA vaccine efficacy.

Authors:  Jing Sun; Dingfeng Li; Yanling Hao; Yuwei Zhang; Wenling Fan; Jingjing Fu; Yunzhang Hu; Yong Liu; Yiming Shao
Journal:  DNA Cell Biol       Date:  2009-05       Impact factor: 3.311

9.  Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects.

Authors:  Chi-Mu Chuang; Archana Monie; Annie Wu; Chien-Fu Hung
Journal:  J Biomed Sci       Date:  2009-05-27       Impact factor: 8.410

10.  Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA.

Authors:  T H Kang; J-Y Chung; A Monie; S I Pai; C-F Hung; T-C Wu
Journal:  Gene Ther       Date:  2009-11-26       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.